Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Not routinely available
NICE (TA195 (SMC 323/06))
01/07/2019
Indication
Severe active rheumatoid arthritis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
100mg/10ml, 500mg/50ml ml solution for intravenous infusion
Comments
January 2007 - To remain on the Additional List, for Specialist Use only (now a licensed indication). August 2010 - NICE MTA advice: SMC advice 323/06 is superseded by NICE TA195. July 2019 (as per LJF) - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.
Link to Advice
Advice Published
25/08/2010